After obtaining encouraging results, we received authorization from the French regulatory agency (ANSM) and The Comité de convenance du CHU de Québec to treat a total of 25 patients, both pediatric and adult, who had venous malformations associated with either PIK3CA mutation (n = 16) or Tie2R (TEK) mutation (n = 9), all demonstrating AKT pathway recruitment within the capillary venous malformations (Fig. 5a–c). Here, PIK3CA is linked to Venous malformation.